Valuing Post-Revenue Biopharmaceutical Assets with Pfizer's Current Portfolio as a Case Study

Yongzhuo Chen, Yixuan Liang, Yiran Liu +2

This research paper addresses the critical challenge of accurately valuing post-revenue drug assets in the biotechnology and pharmaceutical sectors, a key factor influencing a wide…